Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

Summary

The overall objective of this study is to continue to improve the cure rate of childhood acute lymphoblastic leukemia (ALL) in Singapore and Malaysia in the context of a multi-centre cooperative trial using a risk-stratified therapy based primarily on early response to therapy utilizing a simplified minimal residual disease (MRD-lite) platform.

Conditions

• Acute Lymphoblastic Leukemia (ALL)

Interventions

DRUG

Prednisolone

Oral

DRUG

Dexamethasone

Oral

DRUG

L-Asparaginase

Intramuscular injection

DRUG

Vincristine

Intravenous

DRUG

Methotrexate

Intrathecal/ Intravenous/ Oral

DRUG

Daunorubicin

Intravenous

DRUG

Doxorubicin

Intravenous

DRUG

Cyclophosphamide

Intravenous

DRUG

Cytarabine

Intravenous/ Subcutaneous injection

DRUG

6-Mercaptopurine

Oral

DRUG

Thioguanine

Oral

DRUG

Fludarabine

Intravenous

DRUG

Imatinib

Oral (For BCR-ABL ALL only)

Sponsors & Collaborators

• National University Hospital, Singapore

  lead OTHER

Principal Investigators

• Allen Yeoh, MBBS · Ma-spore Group

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

1 Year

Max Age

17 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2008-10-31

Primary Completion

2018-10-31

Countries

• Malaysia
• Singapore

Study Locations